EICHOR
● Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer (SCLC) · Relapsed/Refractory SCLC · Extensive-stage SCLC · Sponsor: Beijing Biotech
About this study
This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3/CD56, DLL3/GD2, and CD56/GD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).
This description comes directly from the study's public registry record.
Talk to the study team
shan S Lu, Phd · +86 13076790030 · Seni-Lu@beijing-biotech.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Peking University Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07744256